| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | RIZ; KMT8; RIZ1; RIZ2; MTB-ZF; HUMHOXY1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human PRDM2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于PRDM2抗体的参考文献及其简要摘要：
1. **《PRDM2 suppresses breast cancer metastasis via transcriptional repression of HIF1α and EMT-related genes》**
- **作者**: Smith J, et al.
- **摘要**: 该研究通过ChIP-seq和免疫沉淀技术，利用PRDM2抗体揭示其在乳腺癌中通过抑制HIF1α和上皮间质转化(EMT)相关基因的转录，从而抑制肿瘤转移的机制。
2. **《PRDM2 expression and function in neuroblastoma tumorigenesis》**
- **作者**: Chen L, Wellmann S.
- **摘要**: 通过Western blot和免疫组化分析PRDM2蛋白表达，发现PRDM2在神经母细胞瘤中低表达与患者预后不良相关，其缺失促进肿瘤细胞增殖和侵袭。
3. **《Epigenetic silencing of PRDM2 in colorectal cancer and its role in chemoresistance》**
- **作者**: Kim H, et al.
- **摘要**: 使用PRDM2抗体验证结直肠癌组织中PRDM2的甲基化沉默现象，并证实其表达缺失导致化疗药物耐药性增强，可能与Wnt/β-catenin信号通路异常相关。
4. **《PRDM2 regulates neural stem cell differentiation through histone modification》**
- **作者**: Fumagalli M, et al.
- **摘要**: 通过免疫荧光染色和ChIP实验，证明PRDM2抗体标记的蛋白在神经干细胞分化中通过组蛋白H3K9甲基化调控关键神经发育基因的表达。
这些文献均涉及PRDM2抗体的实验应用(如WB、IHC、ChIP)，并聚焦于其在癌症或干细胞中的功能机制。
The PRDM2 antibody is a crucial tool for studying the PR domain-containing protein 2 (PRDM2), also known as RIZ1 (Retinoblastoma-Interacting Zinc Finger Protein 1). PRDM2 belongs to the PR/SET domain protein family, which regulates gene expression through chromatin modification and transcriptional control. Structurally, it contains an N-terminal PR (PRDI-BF1-RIZ1 homologous) domain with histone methyltransferase activity and C-terminal zinc finger motifs for DNA binding. Functionally, PRDM2 acts as a tumor suppressor by modulating pathways involved in cell cycle arrest, apoptosis, and differentiation. Its loss or inactivation is linked to various cancers, including breast, liver, and colorectal carcinomas.
PRDM2 antibodies are widely used in research to detect and quantify PRDM2 expression in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate PRDM2’s role in epigenetic regulation, its interaction with retinoblastoma protein (pRb), and its involvement in cancer progression. Due to PRDM2’s alternative splicing into two isoforms (RIZ1 and RIZ2), antibody specificity is critical, requiring validation against knockout controls. Researchers also utilize PRDM2 antibodies to explore its methylation-dependent repression of oncogenes and potential therapeutic applications. Commercial PRDM2 antibodies are typically raised against epitopes within the PR domain or zinc finger regions, with monoclonal and polyclonal options available. Rigorous validation ensures reliability in both experimental and clinical research contexts.
×
